Evidence map›Paper›PMID 41121372›Full record

ArticleOrphanet journal of rare diseases2025

Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.

Huiqiu Zhang, Feipeng Zhai, Menghan Su, Yi Zhang, Jing Ma, Junsen Zhao, Juan Wang, Xueli Chang, Yi Liu, Junhong Guo and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huiqiu Zhang *Department of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Feipeng Zhai *Department of Neurology, Shanxi Provincial People's Hospital, Taiyuan, China.
Menghan Su *Department of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Yi ZhangDepartment of Neurology, Shanxi Provincial People's Hospital, Taiyuan, China.
Jing MaDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Junsen ZhaoDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Juan WangDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Xueli ChangDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China.
Yi LiuDepartment of Neurology, Shanxi Provincial People's Hospital, Taiyuan, China.
Junhong GuoDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China. neuroguo@163.com.
Wei ZhangDepartment of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Street, Taiyuan, 030012, China. zhangvey@126.com.ORCID 0000-0003-4434-5599

Funding

National Natural Science Foundation of China 82471432
6 · The paper itself

Abstract

objectiveThis study aimed to compare the effectiveness of intravenous efgartigimod and intravenous immunoglobulin (IVIg) in patients with Guillain–Barré syndrome (GBS).

methodsThis dual-center, retrospective study analyzed prospectively collected data from adult patients with severe GBS who received either efgartigimod or IVIg. The primary outcome was the proportion of patients who achieving a GBS Disability Scale (GBS-DS) score ≤ 2 at 4 weeks post-treatment. Secondary outcomes included the proportion of patients achieving GBS-DS ≤ 2 at week 24; ≥ 1-grade improvement in GBS-DS at weeks 4 and 24; GBS-DS grade at week 4; and changes in GBS-DS, Medical Research Council (MRC) sum score, and other validated disability measures at weeks 1, 2, 4, 8, 16, and 24. Baseline serum levels of neurofilament light chain (NfL) and anti-GM1 antibodies, and their dynamic changes at 1 week post-treatment were assessed as exploratory outcomes.

resultsTwenty-one patients were enrolled (efgartigimod: n = 9; IVIg: n = 12). The primary outcome was not achieved (OR = 0.67, 95% CI [0.10, 4.48]; P = 1.000). Although most secondary outcomes did not reach statistical significance, the MRC sum score demonstrated significantly greater improvement in the efgartigimod cohort than in the IVIg cohort (P = 0.007). In addition, efgartigimod demonstrated significantly more favorable trajectories of NfL levels and anti-GM1 antibody titers compared with IVIg (P < 0.001).

interpretationEfgartigimod demonstrated superiority in one secondary outcome and two exploratory measures, suggesting its potential as alternative to IVIg in GBS management.

Indexed as

Guillain-Barre SyndromeImmunoglobulins, IntravenousAdultAgedFemaleHumansMaleMiddle AgedNeurofilament ProteinsRetrospective StudiesImmunoglobulins, IntravenousNeurofilament ProteinsAnti-GM1 antibodyEfgartigimodGuillain–Barré syndromeIVIgNeurofilament light chain

Identifiers

PMID41121372
PMCPMC12542069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.